CEO
Cohance Lifesciences Limited
Equibles does not estimate personal net worth.
Amrit Singh is recorded as CEO at Cohance Lifesciences Limited. Amrit Singh has spoken on 3 earnings calls across 1 company, most recently for Cohance Lifesciences Limited on November 6, 2026. Cohance Lifesciences Limited is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
“Specialty chemicals revenue declined 40.6% year-on-year to Rs. 417 million, primarily reflecting lower agrochemical CDMO volumes, pricing pressure, and program phasing.”
“Turning to Specialty Chemicals, the business is progressing through an important portfolio transition. Our near-term priority is to strengthen the existing revenue base while developing a broader set of innovator-led programs across H&M CDMO and performance materials.”
“So, I'm starting from Specialty Chemical. So, Specialty Chemical reported revenue of $2.913 billion in FY26. A marginal decline of 2.1% year-on-year. The business was impacted by customer program phasing, regulatory timing, and generics pressure.”
Cohance Lifesciences Limited
CEO
Transcript header (unverified)
Cohance Lifesciences Limited
Drug Manufacturers - Specialty & Generic · Healthcare
CEO
Earnings Call for the Quarter Ended September 30, 2026
Cohance Lifesciences Limited
Earnings Call
Cohance Lifesciences Limited
Earnings Call for the Quarter Ended March 31, 2026
Cohance Lifesciences Limited
